Validation of the Chinese version of the Liverpool Adverse Events Profile in patients with epilepsy

Epilepsy Research

Volumn 94, Issue 1-2, 2011, Pages 45-52

  Chen, Hsiu Fang ^a,b   Tsai, Yun Fang ^b,c   Shih, Mo Song ^c,d   Chen, Jui Chen ^a  

^a CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d Taiwan Epilepsy Association   (Taiwan)

Author keywords

Chinese version; Epilepsy; LAEP; Reliability; Validity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ACCURACY; ADULT; AGGRESSION; AGITATION; ARTICLE; BLURRED VISION; CHINESE; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; CONCURRENT VALIDITY; CONSTRUCT VALIDITY; CONTENT VALIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG INDUCED HEADACHE; EPILEPSY; FATIGUE; FEMALE; GINGIVA DISEASE; HAIR LOSS; HAND TREMOR; HUMAN; INTERNAL CONSISTENCY; LIVERPOOL ADVERSE EVENTS PROFILE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MONOTHERAPY; MOUTH DISEASE; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; RESTLESSNESS; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; SOMNOLENCE; STOMACH DISCOMFORT; TEST RETEST RELIABILITY; UNSPECIFIED SIDE EFFECT; UNSTEADINESS; VALIDATION STUDY; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; EPILEPSY; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SELF REPORT; TRANSLATING; YOUNG ADULT;

EID: 79952445221     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.01.008     Document Type: Article

References (31)

1. Abetz L., Jacoby A., Baker G.A., McNulty P. Patient-based assessments of quality of life in newly diagnosed epilepsy patients: validation of the NEWQOL. Epilepsia 2000, 41:1119-1128.
2. Arroyo S., Dodson W.E., Privitera M.D., Glauser T.A., Naritoku D.K., Dlugos D.J., Wang S., Schwabe S.K., Twyman R.E. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol. Scand. 2005, 112:214-222. EPMN-106/INT-28 Investigators.
3. Baker G.A., Francis P., Middleton A., Jacoby A., Dafalla B., Young C., Smith D., Chadwick D.W. Development of a patient-based symptom check list to quantify adverse events in persons receiving antiepileptic drugs. Epilepsia 1993, 34(Suppl. 6):18.
4. Baker G.A., Francis P., Middleton A., Jacoby A., Schapel G.J., Dafalla B., Young C., Smith D., Chadwick D.W. Initial development, reliability, and validity of a patient-based adverse drug event scale. Epilepsia 1994, 35(Suppl. 7):80.
5. Baker G.A., Jacoby A., Buck D., Stalgis C., Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia 1997, 38:353-362.
6. Baker G.A., Jacoby A., Francis P., Chadwick D.W. The Liverpool adverse drug events profile. Epilepsia 1995, 36(Suppl. 3):S59.
7. Bootsma H.P., Ricker L., Diepman L., Gehring J., Hulsman J., Lambrechts D., Leenen L., Majoie M., Schellekens A., de Krom M., Aldenkamp A.P. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2007, 10:296-303.
8. Bureau of National Health Insurance, Department of Health, Executive Yuan, Taiwan ROC, 2010. http://www.nhi.gov.tw/02hospital/hospital_file/chap1.doc.
9. Carpay J.A., Aldenkamp A.P., van Donselaar C.A. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005, 14:198-206.
10. Carreno M., Donaire A., Falip M., Maestro I., Fernandez S., Nagel A.G., Serratosa J., Salas J., Viteri C., Llorens J., Baro E. Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy. Epilepsy Behav. 2009, 15:154-159.
11. Carreno M., Gil-Nagel A., Sanchez J.C., Elices E., Serratosa J.M., Salas-Puig J., Villanueva V., Porcel J. Strategies to detect adverse effects of antiepileptic drugs in clinical practice. Epilepsy Behav. 2008, 13:178-183.
12. Cramer J.A., Brandenburg N.A., Xu X., Vera-Llonch M., Oster G. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav. 2007, 11:179-184.
13. Chen C.C., Chen T.F., Hwang Y.C., Wen Y.R., Chiu Y.H., Wu C.Y., Chen R.C., Chen T.H., Liou H.H. Population-based survey on prevalence of adult patients with epilepsy in Taiwan (Keelung community-based integrated screening no. 12). Epilepsy Res. 2006, 72:67-74.
14. Cumbo E., Ligori L.D. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav. 2010, 17:461-466.
15. Elger C., Halasz P., Maia J., Almeida L., Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009, 50:454-463. BIA-2093-301 Investigators Study Group.
16. Food and Drug Administration Drugs @ FDA 2010, U.S. Department of Health and Human Service, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
17. Froscher W., Schier K.R., Hoffmann M., Meyer A., May T.W., Rambeck B., Rosche J. Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord. 2005, 7:237-248.
18. Gilliam F.G., Fessler A.J., Baker G., Vahle V., Carter J., Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004, 62:23-27.
19. Hessen E., Lossius M.I., Reinvang I., Gjerstad L. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia 2006, 47:2038-2045.
20. Kariyawasam S.H., Bandara N., Koralagama A., Senanayake S. Challenging epilepsy with antiepileptic pharmacotherapy in a tertiary teaching hospital in Sri Lanka. Neurol. India 2004, 52:233-237.
21. Krakow K., Lengler U., Rettig K., Schreiner A., Schauble B. Topiramate in add-on therapy: results from an open-label, observational study. Seizure 2007, 16:593-600. TOP-GER-3 investigators.
22. Labiner D.M., Ettinger A.B., Fakhoury T.A., Chung S.S., Shneker B., Tatum Iv W.O., Mitchell Miller J., Vuong A., Hammer A.E., Messenheimer J.A. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009, 50:434-442.
23. Lim D.A., Tarapore P., Chang E., Burt M., Chakalian L., Barbaro N., Chang S., Lamborn K.R., McDermott M.W. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J. Neurooncol. 2009, 93:349-354.
24. Martinez C., Sullivan T., Hauser W.A. Prevalence of acute repetitive seizures (ARS) in the United Kingdom. Epilepsy Res. 2009, 87:137-143.
25. Panelli R.J. The First Seizure Clinic: Psychosocial Characteristics of Patients and the Effect of an Epilepsy Support Program 2010, Swinburne University of Technology.
26. Panelli R.J., Kilpatrick C., Moore S.M., Matkovic Z., D'Souza W.J., O'Brien T.J. The Liverpool Adverse Events Profile: relation to AED use and mood. Epilepsia 2007, 48:456-463.
27. Piperidou C., Karlovasitou A., Triantafyllou N., Dimitrakoudi E., Terzoudi A., Mavraki E., Trypsianis G., Vadikolias K., Heliopoulos I., Vassilopoulos D., Balogiannis S. Association of demographic, clinical and treatment variables with quality of life of patients with epilepsy in Greece. Qual. Life Res. 2008, 17:987-996.
28. Pugliatti M., Beghi E., Forsgren L., Ekman M., Sobocki P. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007, 48:2224-2233.
29. Su C.L., Chang S.E., Chen Z.Y. Prevalence of epilepsy in Ilan Taiwan. Taiwan Epileps. Soc. Bull. 1997, 7:47.
30. Wesnes K.A., Edgar C., Dean A.D., Wroe S.J. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy Behav. 2009, 14:522-528.
31. Wiebe S., Eliasziw M., Matijevic S. Changes in quality of life in epilepsy: how large must they be to be real?. Epilepsia 2001, 42:113-118.